Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis
G P Quinn1, S T Vadaparampil, B Bower
1Moffitt Cancer Center and Research Institute, Division of Cancer Prevention and Control, Tampa, FL, USA. gwen.quinn@moffitt.org
Abstract:
The lifetime risks for both breast and ovarian cancer for BRCA mutation carriers far exceeds the general population risk of 13% for breast cancer and 1.4% for ovarian cancer. BRCA carriers have unique and medically complicated decisions to make regarding their cancer treatment or risk reduction. As BRCA testing becomes increasingly common among unaffected individuals in families with a previously documented BRCA mutation, there are a growing number of individuals with unique psychosocial needs and concerns. This review paper describes the BRCA 1/2 population, discusses preimplantation genetic diagnosis (PGD), and describes the decisions and ethical issues related to PGD among the BRCA 1/ 2 population.
Related Concept Videos
CRISPR
What is Genetic Engineering?
Ethical Dilemmas I
Let us explore some examples to understand the potentially complex moral decisions nurses face.
Take the case of caring for minors, particularly in areas related to reproductive...
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
Ethical Dilemmas II
Ethical Issues
Ethical Concerns in Healthcare:


